



## Amendments to Bylaws

August 5, 2021

RNS Number : 7572H

MaxCyte, Inc.

05 August 2021

### Amendments to Bylaws

GAITHERSBURG, MD, August 5, 2021 - MaxCyte, Inc., (NASDAQ: MXCT) (LSE: MXCT, MXCN) ("MaxCyte" or the "Company"), a leading provider of cell-engineering platform technologies, announces that it has filed amended and restated Bylaws (the "Bylaws") with the U.S. Securities and Exchange Commission on Form 8-K.

In line with the Company's previous announcement on 29 July 2021 relating to the listing of the Company's common stock on Nasdaq, certain rights have been incorporated into the Bylaws which the Company believes stockholders would expect to see in a company whose shares are admitted to trading on a U.S. listed exchange.

Copies of this document can found on the company's website, and be downloaded via the following link:

<https://investors.maxcyte.com/static-files/efd81a4a-09b7-4d8f-a773-d6c1693fa29a>

#### About MaxCyte

MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialisation of next-generation cell therapies. The company's existing customer base ranges from large biopharmaceutical companies -- including 20 of the top 25 pharmaceutical companies based on 2020 global revenue -- to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 13 strategic platform licences to commercial cell therapy developers that allow for more than 75 clinical programmes. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.

#### MaxCyte Contacts:

MaxCyte Inc.

+1 301-944-1660

Doug Doerfler, Chief  
Executive Officer  
Amanda Murphy, Chief  
Financial Officer

*Nominated Adviser and  
Joint Corporate Broker*

+44 (0)20 7886 2500

Panmure Gordon  
Emma Earl / Freddy  
Crossley

Corporate Broking

Rupert Dearden

*Joint Corporate Broker*

**Numis Securities  
Limited**

+44 (0)20 7260 1000

James Black / Duncan  
Monteith / Matthew  
O'Dowd

*Joint Corporate Broker*

**Stifel Nicolaus Europe Limited**

+44 (0)20 7710 7600

Healthcare Investment Banking

Nicholas Moore / Ben Maddison / Samira

Essebiyea

Corporate Broking

Nick Adams

*UK IR Adviser*

**Consilium Strategic  
Communications**

+44 (0)203 709 5700

[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

Mary-Jane Elliott

Chris Welsh

*US IR Adviser*

**Gilmartin Group**

+1 415-937-5400

David Deuchler, CFA

[ir@maxcyte.com](mailto:ir@maxcyte.com)

### **Forward-Looking Statements**

Certain statements made in this press release are forward-looking statements including with respect to the admission of the shares of common stock to trading on AIM. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates" and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including if the shares of

common stock are not admitted to trading on AIM or admission is delayed or if there are adverse market or economic conditions. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this press release. The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCSSFFIIEFSESA